Explore more Johnson & Johnson sites:
Media Center Archive
-
Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaJanssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
-
Real-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer PatientsReal-World Study Confirms Benefit of XARELTO® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
Head-to-head observational analysis showed XARELTO® as effective in treating cancer-associated thromboembolism (CAT) as apixaban
Venous thromboembolism (VTE) is the second-leading cause of death in patients with cancer1 -
Johnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceJohnson & Johnson to Participate in the 41st Annual J.P. Morgan Healthcare Conference
-
Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”)Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”)
-
Johnson & Johnson Names CEO Joaquin Duato as Chairman of the BoardJohnson & Johnson Names CEO Joaquin Duato as Chairman of the Board
Alex Gorsky to Step Down After 30-Year Career at Johnson & Johnson -
Johnson & Johnson Rises to #2 in Ranking of Companies’ Efforts to Expand Access to Medicines WorldwideJohnson & Johnson Rises to #2 in Ranking of Companies’ Efforts to Expand Access to Medicines Worldwide
-
New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient PopulationNew TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
Early skin and enthesitis responses in active psoriatic arthritis patients treated with TREMFYA predicted long-term clinical response, measured at two years, including disease remission
Bio-naïve, TREMFYA-treated patients maintained several disease control endpoints through two years, regardless of baseline characteristics or dosing regimen -
New TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of LifeNew TREMFYA® (guselkumab) Post-Hoc Analysis Reveals Active Psoriatic Arthritis Patients With Early Efficacy Had Meaningful Long-Term Improvement in Health-Related Quality of Life
Post-hoc analysis of DISCOVER-2 Phase 3 data suggest active psoriatic arthritis patients with week 8 response to TREMFYA showed meaningful improvements in health-related quality of life at week 100, compared to patients without early response
Additional post-hoc analyses show treatment with TREMFYA demonstrated improvements of fatigue (FACIT-F scale) at week 8, demonstrating clinically meaningful and durable long-term improvements, with nearly a third maintaining normative levels through week 100 -
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control HypertensionLate-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action -
Janssen’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related AmputationsJanssen’s Save Legs. Change Lives.™ is Creating a More Equitable Future for Communities at Risk of PAD-Related Amputations
Black Americans are up to four times more likely to have a PAD-related amputation,1 largely due to greater delays in care2 and less access to quality vascular care1
Save Legs. Change Lives.™ aims to reach more than 10 million Black Americans over the multi-year initiative